Kissei Pharmaceutical Partners With Reborna Biosciences for Drug Discovery in Genetic Rare Diseases
Kissei Pharmaceutical (TYO:4547) and Reborna Biosciences have signed a research collaboration agreement for drug discovery in genetic rare diseases, according to a Tokyo Stock Exchange filing on Monday.
The collaboration will use Reborna's RNA-targeting small molecule drug discovery technology.
Kissei will provide upfront payments, research expenses, milestone payments, and royalties, and retain global development and commercialization rights for successful compounds.
Price (JPY): $3560.00, Change: $+20, Percent Change: +0.56%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。